JiShi Pharmaceutical-B (02616) to release five latest research findings at the 2025 AACR conference

Intelligenz Finance News App, Basa Pharmaceutical-B (02616) announced that from April 25th to 30th, 2025, the American Association for Cancer Research (AACR) Annual Meeting will be held in Chicago, USA. Basa Pharmaceutical will showcase five independently developed Pipeline 2.0 innovative products at the conference, and will present its latest pre-clinical research results through poster presentations, including three anti-cancer molecules: CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibodies), CS2011 (EGFR/HER3 dual-specific antibodies), and three new ADC molecules from the company's own ADC platform: CS5007(EGFR/HER3 dual-specific ADC), CS5005(ITGB4 ADC), and CS5006(SSTR2 ADC).